4.7 Article

Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria

Journal

BLOOD
Volume 121, Issue 14, Pages 2753-2761

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-11-469353

Keywords

-

Categories

Funding

  1. Leukaemia and Lymphoma Research
  2. Imperial Healthcare Charity
  3. NIHR BRC
  4. Associazione Italiana per la Ricerca sul Cancro (AIRC)
  5. Italian Ministry of Education, University and Research [PRIN 2007HX43y2_002]
  6. Regione Toscana

Ask authors/readers for more resources

The mechanism of bone marrow failure (BMF) in paroxysmal nocturnal hemoglobinuria (PNH) is not yet known. Because in PNH the biosynthesis of the glycolipid molecule glycosylphosphatidylinositol (GPI) is disrupted in hematopoietic stem and progenitor cells by a somatic mutation in the PIG-A gene, BMF might result from an autoimmune attack, whereby T cells target GPI in normal cells, whereas PIG-A mutant GPI-negative cells are spared. In a deliberate test of this hypothesis, we have demonstrated in PNH patients the presence of CD8(+) T cells reactive against antigen-presenting cells (APCs) loaded with GPI. These T cells were significantly more abundant in PNH patients than in healthy controls; their reactivity depended on CD1d expression and they increased upon coculture with CD1d-expressing, GPI-positive APCs. In GPI-specific T cells captured by CD1d dimer technology, we identified, through global T-cell receptor alpha (TCR alpha) analysis, an invariant TCRV alpha 21 sequence, which was then found at frequencies higher than background in the TCR repertoire of 6 of 11 PNH patients. Thus, a novel, autoreactive, CD1d-restricted, GPI-specific T-cell population, enriched in an invariant TCR alpha chain, is expanded in PNH patients and may be responsible for BMF in PNH. (Blood. 2013;121(14):2753-2761)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma

Kanagaraju Ponnusamy, Maria Myrsini Tzioni, Murshida Begum, Mark E. Robinson, Valentina S. Caputo, Alexia Katsarou, Nikolaos Trasanidis, Xiaolin Xiao, Ioannis Kostopoulos, Deena Iskander, Irene Roberts, Pritesh Trivedi, Holger W. Auner, Kikkeri Naresh, Aristeidis Chaidos, Anastasios Karadimitris

Summary: ZBP1-IRF3 axis plays a crucial role in multiple myeloma and may serve as a therapeutic target.

HAEMATOLOGICA (2022)

Article Multidisciplinary Sciences

Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs

Paula Saavedra-Garcia, Monica Roman-Trufero, Hibah A. Al-Sadah, Kevin Blighe, Elena Lopez-Jimenez, Marilena Christoforou, Lucy Penfold, Daria Capece, Xiaobei Xiong, Yirun Miao, Katarzyna Parzych, Valentina S. Caputo, Alexandros P. Siskos, Vesela Encheva, Zijing Liu, Denise Thiel, Martin F. Kaiser, Paolo Piazza, Aristeidis Chaidos, Anastasios Karadimitris, Guido Franzoso, Ambrosius P. Snijders, Hector C. Keun, Diego A. Oyarzun, Mauricio Barahona, Holger W. Auner

Summary: The study reveals the complex mechanisms of proteotoxic stress resolution in cancer cells recovering from chemotherapy-induced stress, involving extensive changes across the transcriptome, proteome, and metabolome, as well as dynamic alterations in glucose and lipid metabolism and suppression of mitochondrial function. Additionally, recovering cells are more vulnerable to specific insults, with a key vulnerability associated with cellular response to amino acid scarcity.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Hematology

Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma

Nikolaos Trasanidis, Alexia Katsarou, Kanagaraju Ponnusamy, Yao-An Shen, Ioannis Kostopoulos, Bien Bergonia, Keren Keren, Paudel Reema, Xiaolin Xiao, Richard M. Szydlo, Pierangela M. R. Sabbattini, Irene A. G. Roberts, Holger W. Auner, Kikkeri N. Naresh, Aristeidis Chaidos, Tian-Li Wang, Luca Magnani, Valentina S. Caputo, Anastasios Karadimitris

Summary: This study successfully identifies adverse prognosis genes in chr1q-amp MM and reveals the important roles of PBX1 and FOXM1 in oncogenic pathways.

BLOOD (2022)

Article Materials Science, Multidisciplinary

Design of a graphene oxide-BODIPY conjugate for glutathione depletion and photodynamic therapy

Giacomo Reina, Amalia Ruiz, Barbara Richichi, Giacomo Biagiotti, Gina E. Giacomazzo, Lucas Jacquemin, Yuta Nishina, Cecilia Menard-Moyon, Wafa T. Al-Jamal, Alberto Bianco

Summary: This study investigates the functionalisation of graphene oxide (GO) with a BODIPY derivative for glutathione (GSH) depletion and photodynamic therapy (PDT). Results show that GO-BODIPY can efficiently deplete intracellular GSH and generate reactive oxygen species, which significantly reduces cell viability after irradiation. The biocompatibility of GO and GO-BODIPY is also demonstrated in prostate adenocarcinoma cells.

2D MATERIALS (2022)

Meeting Abstract Oncology

Single nucletotide polymorphisms of aromatase gene (CYP19A1) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study

Benedetta Conte, Chiara Molinelli, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Anna Turletti, Claudia Bighin, Francesca Poggio, Giulia Buzzatti, Matteo Lambertini, Luca Boni, Lucia Del Mastro

CANCER RESEARCH (2022)

Article Hematology

Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies

Austin G. Kulasekararaj, Morag Griffin, Saskia Langemeijer, Kensuke Usuki, Alexander Kulagin, Masayo Ogawa, Ji Yu, Arshad Mujeebuddin, Jun-ichi Nishimura, Jong Wook Lee, Regis Peffault de Latour

Summary: This study describes the long-term follow-up results of over 400 patients with PNH treated with ravulizumab for 27 weeks to 2 years, showing durable efficacy and good tolerability, highlighting the importance of C5 inhibitors as the mainstay of PNH treatment.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

Review Hematology

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas

Franck Morschhauser, Gilles Salles, Connie Lee Batlevi, Herve Tilly, Aristeidis Chaidos, Tycel Phillips, John Burke, Ari Melnick

Summary: This review discusses the mechanisms and therapeutic targets of EZH2 in B-cell lymphomas, as well as the potential synergy of EZH2 inhibitors with existing treatments.

BLOOD REVIEWS (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

Repeatability and test-retest reproducibility of mean apparent diffusion coefficient measurements of focal and diffuse disease in relapsed multiple myeloma at 3T whole body diffusion-weighted MRI (WB-DW-MRI)

Khalil ElGendy, Tara D. Barwick, Holger W. Auner, Aristeidis Chaidos, Kathryn Wallitt, Antoni Sergot, Andrea Rockall

Summary: The study evaluated the reproducibility and intra/interobserver agreement of ADC measurements of myeloma lesions using WB-DW-MRI at 3T MRI. Results showed excellent intraobserver agreement but poorer interobserver agreement for certain lesion types. Test-retest reproducibility was high for mean ADC measurements, with some variations observed between lesion types and body regions.

BRITISH JOURNAL OF RADIOLOGY (2022)

Review Medicine, General & Internal

Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition

Rosario Notaro, Lucio Luzzatto

Summary: Inhibitors of proximal and terminal complement cascades can control red-cell hemolysis associated with paroxysmal nocturnal hemoglobinuria, but some patients may still experience breakthrough hemolysis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Review Hematology

Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs*

Corrado Girmenia, Wilma Barcellini, Paola Bianchi, Eros Di Bona, Anna Paola Iori, Rosario Notaro, Simona Sica, Alberto Zanella, Antonio De Vivo, Giovanni Barosi, Antonio Risitano

Summary: This article presents the results of group discussion among experts on unmet clinical needs in managing infectious risk associated with eculizumab or new terminal complement inhibitors (CIs) in paroxysmal nocturnal hemoglobinuria (PNH). The selected clinically relevant needs were optimizing infection prevention measures, developing non-pharmacological infectious risk-mitigation strategies, and improving disease management during infectious complications. Consensus opinions and proposals for advancing clinical practice were provided for each issue. The aim is to improve CI therapy and guide future studies in this field.

BLOOD REVIEWS (2023)

Article Chemistry, Organic

Benzo[c][1,2]thiazine-Based Analogs in the Inverse Electron Demand [4+2] Hetero Diels-Alder Reaction with Glycals: Access to Tetracyclic Fused Galactose and Fucose Derivatives

Giacomo Biagiotti, Laura Legnani, Giusi Aresta, Maria A. Chiacchio, Barbara Richichi

Summary: This study describes the synthesis and reactivity of a new class of electron-poor heterodienes in an [4+2] inverse electron demand hetero Diels-Alder reaction. The highly reactive electrophiles allow for the selective synthesis of unprecedented benzo-thiazine glyco-fused derivatives. Experimental and computational data confirm the feasibility of the reaction.

EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2022)

Letter Hematology

The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab

Michela Sica, Federica Barone, Caterina Nannelli, Patrizia Ricci, Luana Marano, Maria De Angioletti, Eros Di Bona, Antonio M. Risitano, Rosario Notaro

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Chemistry, Medicinal

Rational design, synthesis, and pharmacological evaluation of a cohort of novel beta-adrenergic receptors ligands enables an assessment of structure-activity relationships

Jacopo Tricomi, Luca Landini, Valentina Nieddu, Ugo Cavallaro, Jillian G. Baker, Athanasios Papakyriakou, Barbara Richichi

Summary: Over the past decade, the biomedical applications of molecules that can modulate beta-adrenergic signaling have gained increasing attention, especially in cancer treatment. However, the identification of selective beta-adrenergic receptor (beta-AR) ligands for pharmacological studies and drug development remains a challenging task due to the complexity and specificity requirements of beta-ARs. In this study, we synthesized and evaluated a series of structurally diverse compounds (MC) based on the aryloxy-propanolamine scaffold of SR59230A, aiming to gain insights into the structure-activity relationships of the three beta-AR subtypes. The results provide valuable information on key structural elements and substituents that control the activity and selectivity of these compounds, which could facilitate the development of selective beta-AR drugs.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Multidisciplinary

Graphene Oxide-BODIPY Conjugates as Highly Fluorescent Materials

Giacomo Reina, Giovanni Mariano Beneventi, Ramandeep Kaur, Giacomo Biagiotti, Alejandro Cadranel, Cecilia Menard-Moyon, Yuta Nishina, Barbara Richichi, Dirk M. Guldi, Alberto Bianco

Summary: Covalent functionalization of graphene oxide (GO) with boron dipyrromethenes (BODIPYs) was achieved, resulting in two different GO-BODIPY conjugates with different properties. The use of a long, flexible spacer led to strong electronic GO-BODIPY interactions, affecting light absorption and excitation. On the other hand, a short, rigid spacer resulted in minor electronic interactions and selective excitation of PBA-BODIPY, allowing the investigation of excited state interactions. Additionally, reversible covalent linkage between GO and PBA-BODIPY enabled slow release and imaging.

CHEMISTRY-A EUROPEAN JOURNAL (2023)

Article Multidisciplinary Sciences

Identification and characterization of novel ETV4 splice variants in prostate cancer

Irene Cosi, Annalisa Moccia, Chiara Pescucci, Uday Munagala, Salvatore Di Giorgio, Irene Sineo, Silvestro G. G. Conticello, Rosario Notaro, Maria De Angioletti

Summary: ETV4, an overexpressed ETS protein in prostate cancer, promotes migration, invasion, and proliferation in prostate cells. This study identifies previously unknown ETV4 alternatively spliced transcripts in human prostate cell lines and confirms their presence in prostate tumors. The abundance of these transcripts may reflect tumor deranged splicing machinery and their potential interactions with canonical variants may contribute to the biology and clinics of prostate cancer. Further investigations are needed to understand the biological role of these ETV4 transcripts and their isoforms.

SCIENTIFIC REPORTS (2023)

No Data Available